RxDoctor Payments DataLook up a doctor →

Paul Denker, MD

Endocrinology, Diabetes & Metabolism · Palm Harbor, FLNPI 1750328811

Payments from drug & device makers

$245,384in general payments, 2019–2025

Across 1,184 payments — averaging $207.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$156K
  • Pfizer$34K
  • Sanofi US Services Inc.$27K
  • Lexicon Pharmaceuticals, Inc.$12K
  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS261$155,524
Pfizer13$33,720
Sanofi US Services Inc.15$27,405
Lexicon Pharmaceuticals, Inc.1$11,560
Novo Nordisk145$2,643
Lilly USA, LLC96$1,541
Sanofi-aventis U.S. LLC59$1,379
Amgen(2 entities)59$1,199
AstraZeneca(2 entities)46$1,157
Boehringer Ingelheim47$948
Abbott47$722
Xeris Pharmaceuticals, Inc.39$611
Mannkind Corporation24$580
IBSA Pharma Inc.27$554
Corcept Therapeutics22$418
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$409
Dexcom, Inc.22$394
Bayer20$386
Antares Pharma, Inc.20$374
Amneal Pharmaceuticals LLC19$315
UCB, Inc.21$291
Amarin Pharma, Inc.14$278
Insulet Corporation10$214
Radius Health, Inc.12$209
Lifescan, Inc.14$189
BETA Bionics, Inc.8$178
Merck9$176
Zealand Pharma US, Inc.6$148
Nevro Corp.7$140
Ultragenyx Pharmaceutical Inc.6$137
GRT US Holding, Inc.8$133
Astellas Pharma US Inc1$123
Recordati_rare_diseases_inc.5$107
Aurinia Pharma U.S., Inc.4$98
AbbVie4$85
Medtronic(2 entities)4$78
Otsuka America Pharmaceutical, Inc.3$76
Novartis4$69
Halozyme Inc4$68
Embecta Corp.3$57
Acerus Pharmaceuticals Corporation2$50
Tandem Diabetes Care, Inc.2$46
Ipsen Biopharmaceuticals, Inc2$45
Cequr Corporation2$40
Valeritas, Inc.2$39
Merz Pharmaceuticals, LLC1$38
Johnson & Johnson3$38
Exact Sciences2$33
Esperion Therapeutics, Inc.2$32
Neurocrine Biosciences, Inc.1$30
Currax Pharmaceuticals LLC2$29
E.r. Squibb & Sons, L.L.C.1$28
ANI Pharmaceuticals, Inc.1$26
Madrigal Pharmaceuticals1$25
Verity Pharmaceuticals Inc.1$25
Renalytix AI, Inc.1$22
Shire North American Group Inc1$21
Regeneron Healthcare Solutions, Inc.1$21
Kyowa Kirin, Inc.1$21
Vivus LLC1$20

How this compares

$245,384 in reported general payments places this provider in the 90th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$46,909
Medicare patients
204
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Palm Harbor

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →